论文部分内容阅读
抗体导向的酶催化前体药物疗法 ( ADEPT)利用抗体与抗原 ,酶与底物的双重选择特异性 ,进行抗癌药物的前体药物研究 ,提高抗癌药物对肿瘤细胞的选择性 ,降低毒性 ,提高治疗指数。有关苯甲酸氮芥的 ADEPT研究已进入临床研究阶段 ,并取得了一定的成绩。本文就活性酶与抗体的选择及其抗体 -酶偶联物的构成、前体药物设计、体外和体内活性研究方法等内容进行综述 ,展示ADEPT研究的进展
Antibody-directed enzyme catalyzed prodrug therapy (ADEPT) utilizes the dual-selective specificity of antibodies and antigens, enzymes and substrates to conduct prodrug studies of anticancer drugs to increase the selectivity of anticancer drugs on tumor cells and reduce toxicity. , increase the treatment index. The ADEPT study on benzoic acid mustard has entered the clinical research stage and has achieved certain results. This article reviews the selection of active enzymes and antibodies, the composition of their antibody-enzyme conjugates, the design of prodrugs, in vitro and in vivo activity research methods, etc., to demonstrate the progress of ADEPT research.